Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Volunteers
Health Professionals
What is the purpose of this trial?
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Alison Johnson
- Anca Bulgaru, MD
- Andrea Brennan
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- D. Barry Boyd, MD, MS
- Daniel P. Petrylak, MD
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Harold Tara Jr, MD
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Joseph Kim, MD
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Karishma Mehra, MBBS
- Katelyn Scott
- Kayla Martello
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Lynn Mastrianni
- M. Sung Lee, MD
- Madeline Santiago
- Melissa Gambaccini
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Michael Grant, MD
- Michael Hurwitz, MD, PhD
- Michelle Laspino
- Neal Fischbach, MD
- Osarugue Otasowie
- Pamela L. Kunz, MD
- Pawan Karanam, MD
- Renee Moye
- Robert Legare, MD
- Samantha Couillard
- Sara Anastasio, RN
- Sarah Carlson
- Sarah Thomen, APRN
- Sharynn Hall, MD, PhD
- Stacey LaRosa
- Stacey Stein, MD
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Teresa White
- Vanna Dest
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Zia Rahman, MD
- Last Updated07/03/2024
- Study HIC#2000035795